Cleveland Diagnostics Announces Inclusion of IsoPSA® in National Comprehensive Cancer Network® Guide
NCCN® Guidelines now include IsoPSA to further define the probability of high-grade prostate cancerCLEVELAND--(BUSINESS WIRE)--Cleveland Diagnostics, Inc., a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today that its prostate cancer t...
Source: pharmiweb.com